ARTES Biotechnology joins TA101 GOCLIN
A leading consortium of industrial partners has been awarded a grant by the Seventh Framework Program of the European Union for an innovative research and development project “TA101 GOCLIN: Clinical development of TA-101 for the treatment of rheumatoid arthritis“ (#606352). The aim of this Project is to take TA101, a small domain antibody developed by TechnoPhage, into the clinical stage of development for rheumatoid arthritis (RA) and develop a novel mode of administration for the market of biologic therapeutics. The project is forecasted for completion in 2015, with a total duration of 26 months. The total budget is EUR 1,72 million corresponding to a total European funding of EUR 1,36 million.
TA101 GOCLIN has mobilized the critical mass of seven industrial partners from 5 European countries. These partners are from Belgium, France, Germany, The Netherlands and Portugal.
Amspar B.V will design and develop an integrated microneedle patch combination loaded with TA_101. In this regard, Amspar will closely work together with Laboratoires Plasto Santé (expert in pharmaceutical patch development) and MicroCreate BV (microneedle array manufacturing).
Q-Biologicals NV together with ARTES Biotechnology GmbH will develop a suitable microbial expression host and manufacturing process. cGMP material for clinical trials will be produced by Q-Biologicals.
Clinical trials will be conducted by SGS Life Science Services.
